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Abstract
Tumor necrosis factor (TNF) has been implicated in inflammation-associated tumor progression. Although multi-
ple reports identified a role for TNF signaling in established cancers, few studies have assessed the impact of TNF
blockade on early tumor formation promotion. We aimed at exploring the effects of TNF neutralization in a preclinical
mouse model of lung carcinogenesis. For this, Balb/c mice (n = 42) received four weekly intraperitoneal urethane
injections (1 g/kg) and twice-weekly intraperitoneal soluble TNF receptor (etanercept; 10 mg/kg) administered during
tumor initiation/promotion, tumor progression, or continuously (months 1, 6, and 1-8 after urethane start, respectively).
Lung oncogenesis was assessed after 8months. In separate short-term studies, Balb/cmice (n=21) received a single
control or urethane injection followed by twice-weekly intraperitoneal control or sTNFR:Fc injections. Lung inflam-
mation was assessed after 1 week. We found that sTNFR:Fc treatment during tumor initiation/promotion resulted in
a significant reduction of tumor number but not dimensions. However, sTNFR:Fc administered during tumor progres-
sion did not impact tumormultiplicity but significantly decreased tumor diameter. Continued sTNFR:Fc administration
was effective in halting both respiratory tumor formation and progression in response to urethane. This favorable
impact was associated with impaired cellular proliferation and new vessel formation in lung tumors. In addition, TNF
neutralization altered the lung inflammatory response to urethane, evidenced by reductions in TNF and macrophage
and increases in interferon γ and interleukin 10 content of the air spaces. sTNFR:Fc treatment of RAW264.7 macro-
phages downregulated TNF and enhanced interferon γ and interleukin 10 expression. In conclusion, TNF neutralization
is effective against urethane-induced lung oncogenesis in mice and could present a lung chemoprevention strategy
worth testing clinically.
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Introduction
Lung cancer presents a contemporary global pandemic responsible for
an estimated 13% (1.6 million) of cancer cases and 18% (1.4 million)
of cancer deaths worldwide in 2008 [1]. Current evidence indicates
that the death toll of lung cancer is expected to rise further, especially
in developing countries [2]. Moreover, adenocarcinoma, a histologic
subtype of non–small cell lung carcinoma, presents the bulk of new
disease and is steeply rising in incidence, in particular among women
[3]. Although smoking cessation constitutes the mainstay of lung can-
cer prevention, most lung cancers are currently diagnosed in former
smokers [4], and many cases occur in never smokers [5]. Moreover,
chronic inflammatory diseases of the respiratory tract, such as chronic
obstructive pulmonary disease (COPD), promote carcinogenesis inde-
pendent from smoking [3,6]. These highlight the need for the devel-
opment of strategies for early detection and chemoprevention of lung
cancer, in addition to tobacco control [7,8].
Tumor necrosis factor (TNF), a multifunctional proinflammatory
cytokine initially found to inhibit tumor growth through hemor-
rhagic necrosis [9], has recently been implicated as a key promoter of
inflammation-associated malignant tumor progression and metasta-
sis [10,11]. For example, TNF participates in an autocrine growth-
promoting signaling network enabling the intraperitoneal spread of
established ovarian cancer [12]. However, far less is known on the
functions of the cytokine in early phases of carcinogenesis, such as
tumor initiation and promotion. In the lungs, TNF and its receptors
(TNFRs) are expressed by lung cancer cells [13,14] and TNF signals
integrated by cancer cell nuclear factor (NF)-κB transcriptional activa-
tion function to accelerate tumor cell growth [11]. In a mouse model
of multistage lung oncogenesis induced by the carcinogen urethane, we
have previously shown that epithelial NF-κB drives both carcinogen-
induced inflammation and neoplasia starting from early stages of onco-
genesis, with TNF presenting a possible downstream effector of NF-κB
signaling [15]. Earlier elegant work that used genetic targeting of the
murine Tnf gene showed that Tnf-deficient mice are protected from
urethane-induced tumorigenesis [16]. Although this evidence directly
implicates TNF as an important mediator of lung tumor initiation
and promotion, no effort has been undertaken to pharmacologically
block TNF signaling in preclinical lung cancer models.
In the present work, we aimed at investigating the effects of TNF
neutralization in a preclinical mouse model of lung carcinogenesis in-
duced by repeated administration of the respiratory carcinogen urethane
to sensitive Balb/c mice. TNF bioactivity was blocked using soluble
TNF receptors (sTNFR) coupled to constant immunoglobulin frag-
ment (Fc) during distinct time frames of tumor initiation/promotion
and/or progression. Our findings indicate that this strategy is effective
in ameliorating experimental chemical lung oncogenesis by favorably
impacting both tumor initiation/promotion and progression.
Materials and Methods
Reagents
sTNFR:Fc (etanercept, Enbrel; Wyeth Hellas SA, Athens, Greece),
a dimeric fusion protein consisting of the extracellular ligand-binding
portion of the human 75-kDa TNF receptor linked to the Fc portion
of human IgG1, was purchased from the pharmacy [13]. Urethane
(ethyl carbamate) was from Sigma-Aldrich (St Louis, MO). 3-(4,5-
Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium, inner salt (MTS) assay was from Promega (Madison,
WI), anti–proliferating cell nuclear antigen (PCNA) antibody from
Santa Cruz Biotechnology (Santa Cruz, CA), terminal deoxynucleotidyl
nick-end labeling (TUNEL) kit was fromRocheMolecular Biochemicals
(Penzberg, Germany), anti–factor VIII–associated protein (F8A) anti-
body was from Invitrogen (San Francisco, CA), and mouse cytometric
bead array (CBA) assaying TNF, interferon (IFN) γ, monocyte chemo-
attractant protein 1 (C-C motif chemokine ligand 2), interleukin 6
(IL-6), IL-10, and IL-12p70 (detection limits: 7.3, 2.5, 52.7, 5.0, 17.5,
and 10.7 pg/ml, respectively) was fromBDBiosciences (San Jose, CA).
Animal Experiments
Wild-type Balb/c mice were purchased from the Hellenic Pasteur In-
stitute (Athens, Greece) and inbred at the animal care facilities of the
General Hospital Evangelismos (Athens, Greece). All animal care and
experimental procedures were approved by the Veterinary Administra-
tion Bureau of the Prefecture of Athens, Greece, and were conducted
according to international standards (http://grants.nih.gov/grants/
olaw/GuideBook.pdf; http://ec.europa.eu/environment/chemicals/
lab_animals/legislation_en.htm). Experimental mice were sex, weight
(20-24 g), and age (8-10 weeks) matched. For induction of chemical
multistage lung adenocarcinogenesis, 42 mice received four weekly in-
traperitoneal (i.p.) injections of urethane (1 g/kg in 200 μl of phosphate-
buffered saline [PBS]). sTNFR:Fc (10 mg/kg in 100 μl of PBS i.p.)
was administered twice-weekly during distinct time frames of tumor
initiation/promotion (month 1 after urethane start), tumor progres-
sion (month 6 after urethane start), or continuously (months 0-8 after
urethane start), at days 2 and 5 of each experimental week, whereas
control mice received PBS (100 μl i.p.). This twice-weekly dosing regi-
men of sTNFR:Fc has been shown in the literature to effectively neu-
tralize endogenous TNF bioactivity in humans andmice [17–19].Mice
were killed at day 240 after urethane initiation. In short-term stud-
ies, 21 mice received a single i.p. injection of PBS control or urethane
(1 g/kg in 200 μl of PBS), followed by PBS control or sTNFR:Fc
(10 mg/kg in 100 μl of PBS i.p.) on days 2 and 5 after urethane. Mice
were killed at day 7 after urethane.
Assessment of Lung Inflammation
Bronchoalveolar lavage (BAL) was performed with three aliquots of
1000 μl of sterile ice-cold PBS. Fluid was combined and centrifuged at
260g for 10 minutes to separate cells from supernatant. The cell pellet
was resuspended in 1 ml of PBS with 1% bovine serum albumin, and
the total cell count was determined using a grid hemocytometer. Cell
differentials were obtained by counting at least 400 cells on Wright-
Giemsa–stained cytocentrifugal (cytospin) specimens (Three Step Stain
Set; Richard-Allen Scientific, Kalamazoo, MI). Total cell numbers in
BAL were then calculated by multiplying the percentage of each cell
type by the total number of BAL cells. Inflammatory cytokines were
determined in cell-free BAL supernatants by CBA as described previ-
ously [15]. Protein levels were determined using the albumin protein
assay (Hercules, CA). Cytokine levels were corrected for BAL protein
and given as nanograms per gram of protein.
Assessment of Lung Oncogenesis
The lungs were explanted after transtracheal inflation with 10%
neutral-buffered formalin under 25 cm H2O pressure. Lung tumors
were counted by four blinded readers (S.P.K., C.A.K., I.P., and
G.T.S.) under a stereomicroscope (Stemi DV4; Zeiss, Jena, Germany)
using surface and transillumination to visualize intrapulmonary tumors
and averaged as described previously [15,16,20]. Tumor diameter (δ)
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was determined using microcalipers, and tumor volume (V ) was de-
termined using the formula: V = πδ3/6. Total tumor burden for
each mouse was calculated by adding the volumes of all tumors from
the lungs of each mouse. Excised mouse lungs were fixed in 10%
neutral-buffered formalin for 24 hours. Lungs were embedded in paraf-
fin based on the lung base, and 5-μm-thick sets (10 each) of serial trans-
verse sections were cut at three levels of the lungs (apical, median, and
basal). Sections were mounted on glass slides and stained with hema-
toxylin and eosin. The total number and the fraction of total lung
lesions consisting of each type of distinct lung lesions, including hyper-
plasia (atypical alveolar and bronchial epithelial hyperplasia), adenoma,
and adenocarcinoma, on the sections from each lung were evaluated
by two blinded readers (S.P.K. and G.T.S.), according to guidelines
of the Mouse Models of Human Cancers Consortium [21]. Alter-
natively, tissue sections were immune-labeled for PCNA, TUNEL,
and F8A, as described previously [13,15,22]. The number of immuno-
reactive cells in lung tumors was evaluated by two blinded readers
(S.P.K. and G.T.S.) in at least five high-power visual fields of at least
five different tumors. The results were averaged per mouse.
Cellular Experiments
Mouse lung adenocarcinoma (Lewis lung carcinoma, LLC) and
bone marrow–derived macrophages (RAW264.7) were purchased from
the American Type Culture Collection (Manassas, VA), and experi-
ments were done within 6 months. The cell lines were validated by
the manufacturer using the short tandem repeat method. Cells were
cultured at 37°C in 5% CO2–95% air using Dulbecco modified Eagle
medium 10% fetal bovine serum supplemented with glutamine and
100 mg/l penicillin/streptomycin. For experiments, cells were plated
at equal densities and incubated with PBS or various concentrations
of sTNFR:Fc. Cell proliferation was determined using MTS reduction
[22]. Cellular mediator elaboration was assessed using CBA of cell-free
cell culture supernatants and was corrected for protein content, similar
to BAL samples.
Statistics
All values given represent mean ± SEM. To compare variables
between multiple groups, one-way analysis of variance with the Tukey
post hoc tests or Kruskal-Wallis test with the Dunn post hoc tests were
used for normally and not normally distributed variables, respectively.
All P values are 2-tailed. P < .05 was considered significant. Statistical
analyses were performed, and graphs were created using Prism Software
Version 5.0 (GraphPad, La Jolla, CA).
Results
Early TNF Neutralization Significantly Inhibits Tumor
Initiation/Promotion Induced by Urethane in Balb/c Mice
In initial long-term tumor control experiments designed to deter-
mine the impact of TNF neutralization on urethane-induced lung
carcinogenesis, 42 Balb/c mice received four consecutive weekly i.p.
injections of 1 g/kg urethane. Twice-weekly i.p. drug treatment was
started immediately after the first urethane dose in four different
protocols: control mice received PBS continuously for 8 months, mice
enrolled in a tumor initiation/promotion trial received sTNFR:Fc
during the first month and PBS thereafter, mice enrolled in a tumor
progression trial received sTNFR:Fc during the sixth month and PBS
before and thereafter, and mice enrolled in a prolonged prevention trial
received sTNFR:Fc continuously for 8 months (Figure 1A). All mice
survived to termination at 8 months and did not show signs of sick-
ness as evidenced by body mass and overall behavior. Compared with
controls (mean lung tumor number = 16.0 ± 1.6 and diameter = 1.01 ±
0.07 mm), mice of the tumor initiation/promotion trial developed
lung tumors of similar size (mean diameter = 1.07 ± 0.03 mm, P >
.05), but of significantly decreased multiplicity (mean number =
9.7 ± 1.1, P < .05; Figure 2, A-C ). Mean lung tumor volume and
overall lung tumor burden per mouse were not affected by sTNFR:
Fc treatment in the tumor initiation/promotion protocol (Figure 2,
D and E), but fewer adenomas developed in this group compared with
controls, with a corresponding increase in the relative abundance of
less progressed preneoplastic lesions (Figure 2F ). These results indicated
that blockade of TNF signaling during early phases of urethane-
induced lung oncogenesis is effective in limiting the development of
new preneoplastic lesions in the respiratory tract of Balb/c mice.
TNF Antagonism at Late Time Points after Urethane
Significantly Inhibits Tumor Progression
We next examined the lungs of mice enrolled in the tumor progres-
sion trial, which received sTNFR:Fc only during the sixth month after
urethane start (Figure 1A). Compared with controls, these mice devel-
oped a similar number of lung tumors (mean lung tumor number =
14.3 ± 1.1, P > .05; Figure 2, A and B). However, lung tumors in this
group were of markedly decreased dimensions (mean diameter = 0.71 ±
0.07 mm, P < .01) compared with controls (Figure 2, A and C), result-
ing in significantly reduced mean lung tumor volume and overall lung
tumor burden per mouse (Figure 2,D and E). Similar to mice enrolled
in the tumor initiation/promotion trial, fewer adenomas developed in
this group, with a corresponding increase in the relative abundance
of hyperplastic lesions (Figure 2F ). These results indicated that TNF
neutralization during late phases of urethane-induced lung tumori-
genesis does not impact tumor initiation/promotion but significantly
retards the growth and progression of established neoplastic lesions.
Figure 1. Experimental setup of in vivo studies. (A) Long-term stud-
ies: 42 Balb/c mice received intraperitoneal urethane (four weekly
doses of 1 g/kg) and concomitant twice-weekly intraperitoneal
PBS (control) or sTNFR:Fc (10 mg/kg) during months 1, 6, or 0 to
8 after urethane start. 4EC, month of administration of four urethane
(ethyl carbamate, EC) injections; n = sample size; each box repre-
sents 1 month; gray boxes indicate periods of sTNFR:Fc treatment.
(B) Short-term studies: Balb/c mice received intraperitoneal PBS
(control) or urethane (a single dose of 1 g/kg) followed by intra-
peritoneal PBS (control) or sTNFR:Fc (10 mg/kg) at days 2 and 5
after urethane. 1EC, day of administration of a single urethane (ethyl
carbamate, EC) injection; n = sample size; each box represents
1 day; gray boxes indicate days of sTNFR:Fc treatment.
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Continuous Inhibition of TNF Signaling Halts Both
Urethane-Induced Tumor Initiation/Promotion
and Progression
Finally, lungs of mice that received continuous sTNFR:Fc treatment
were analyzed (prolonged prevention trial; Figure 1A). Compared with
controls, these mice displayed marked reductions in all parameters of
oncogenesis examined, including lung tumor multiplicity (mean lung
tumor number = 9.9 ± 1.0, P < .01), tumor size (mean diameter =
0.76 ± 0.03 mm, P < .01), mean lung tumor volume, overall lung
tumor burden per mouse, as well as in the relative abundance of more
progressed adenoma lesions (Figure 2). These results indicated that
prolonged therapeutic TNF inhibition during the whole time course
of urethane-induced lung tumorigenesis is effective in halting both
tumor initiation/promotion and progression.
TNF Neutralization Inhibits Lung Tumor Cell Proliferation
and New Vessel Formation within Lung Tumors
To further characterize the antitumorigenic effects of sTNFR:Fc, we
immune-labeled proliferating and apoptotic tumor cells using PCNA
and TUNEL, respectively. Although no immunoreactivity for TUNEL
was identified in any group at the 8-month time point (data not shown),
the percentage of tumor cells displaying immunoreactivity for PCNA
(proliferating cells) was significantly decreased in animals that received
late or continuous sTNFR:Fc treatment (tumor progression and pro-
longed prevention trials; Figure 3,A and B). Newly formed blood vessels
within de novo developed lung tumors were then sought for using anti-
F8A immune labeling. Microvascular density was equal between tumors
in the control, tumor initiation/promotion, and tumor progression arms
but was markedly inhibited in mice that received prolonged courses of
sTNFR:Fc (prolonged prevention trial; Figure 3, C and D). These data
indicated that TNF exerts tumor growth– and angiogenesis-promoting
effects within chemical-induced lung tumors, which can be effectively
abrogated by its therapeutic targeting.
sTNFR:Fc Treatment Modulates Urethane-Induced
Pulmonary Inflammation
Because urethane-induced lung carcinogenesis is intimately asso-
ciated with a lung inflammatory response [15] and TNF is a major
Figure 2. Effects of sTNFR:Fc-mediated TNF neutralization on urethane-induced lung carcinogenesis in Balb/c mice. (A) Representative
photographs of tumor-bearing lungs (black arrowheads point to tumors). Scale bar, 1 cm. (B-E) Lung tumor evaluation results at
8 months, including tumor number (B), mean diameter (C), mean volume (D), and cumulative volume per lung (E). Dots indicate raw
data points; lines, mean; bars, SEM. (F) Histologic typing of neoplastic lesions at 8 months. AC indicate adenocarcinoma; columns,
mean; bars, SEM; P, overall probability. *P < .05, **P < .01, and ***P < .001 compared with control.
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proinflammatory mediator [10], we questioned whether our interven-
tions into TNF signaling would alter inflammatory parameters during
urethane-induced oncogenesis in the lungs. For this, BAL immune cell
and cytokine content of our previously described experimental mice
were analyzed. Compared with controls, mice enrolled in the tumor
initiation/promotion trial had reduced BAL macrophages and lympho-
cytes; mice of the tumor progression trial decreased BAL macrophages,
neutrophils, and lymphocytes; and mice that received continuous
sTNFR:Fc decreased numbers of BAL macrophages only (Figure 4A).
Regarding BAL inflammatory mediator content, none of the molecules
tested (TNF, IFN-γ, MCP-1, IL-6, IL-10, and IL-12p70) were down-
regulated by sTNFR:Fc treatment in any regimen. On the contrary,
IFN-γ and IL-10, mediators with known anti-inflammatory and im-
mune surveillance functions [23,24], were upregulated specifically by
continuous sTNFR:Fc treatment (Figure 4). To better understand
how TNF neutralization impacts urethane-induced inflammation in
the lungs, we performed a short-term study. For this, Balb/c mice re-
ceived a single urethane dose or PBS control, followed by twice-weekly
sTNFR:Fc or PBS control and were killed after 1 week (Figure 1B).
Compared with PBS-treated controls, urethane-treated mice showed
increased BAL macrophage and TNF content, in accord with a pre-
vious work [15]. Mice that received both urethane and sTNFR:Fc
had BAL macrophage numbers and TNF levels that were reduced com-
pared with urethane-only–treated animals and were similar to those ob-
served in PBS-only–treated mice. Interestingly, the latter group of mice
that received urethane and sTNFR:Fc had increased BAL IFN-γ and
IL-10 levels (Figure 5). These data indicated that sTNFR:Fc treat-
ment downregulated monocytic inflammation and proinflammatory
TNF expression in the air space compartment in response to urethane,
at the same time boosting anti-inflammatory IFN-γ and IL-10 expres-
sion. Collectively, these findings suggested that, in addition to critical
tumorigenesis-related events such as cell-autonomous proliferation and
angiogenesis, TNF blockade alters yet another conditional hallmark of
cancer development—cancer-related inflammation [25].
TNF Neutralization Suppresses TNF and Augments IFN-γ
and IL-10 Elaboration by Mouse Macrophages In Vitro
We subsequently sought to explain the previously mentioned find-
ings of sTNFR:Fc-induced TNF-suppression and IFN-γ and IL-10
up-regulation observed in our experimental animals. Because airway
Figure 3. Effects of sTNFR:Fc treatment on tumor growth and neoangiogenesis. Balb/c mice were treated as outlined under Figure 1A.
(A) Percentage of tumor cells showing immunoreactivity for PCNA. (B) Representative images of PCNA immunoreactivity. (C) Number of
factor VIII–associated protein (F8A)–reactive cell clusters per high-power field (hpf). (D) Representative images of F8A immunoreactivity.
(A, C) Dots indicate raw data points; lines, mean; bars, SEM; P, overall probability. *P < .05, **P < .01, and ***P < .001 compared with
control. (B) Å = 400. Scale bar, 200 μm. Brown indicates PCNA immunoreactivity; blue, hematoxylin nuclear counterstaining. (D) Å = 600.
Scale bar, 150 μm. Arrows point to brown F8A-immunoreactive cell clusters; blue indicates hematoxylin nuclear counterstaining.
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epithelial cells and alveolar macrophages are the main cell popula-
tions with secretory capabilities into the air space compartment, we
hypothesized that sTNFR:Fc treatment would enhance TNF and
suppress IFN-γ and IL-10 elaboration by either cell type. To model
airway epithelial cells and alveolar macrophages in vitro, we used mu-
rine airway epithelial-originated carcinoma (LLC) and bone marrow–
derived macrophage (RAW264.7) cells. sTNFR:Fc treatment of these
cell lines had no effect on cell proliferation assessed using a MTS assay
(data not shown). In addition, TNF neutralization did not impact
mediator (TNF, IFN-γ, MCP-1, IL-6, IL-10, and IL-12p70) elabora-
tion by LLC cells (data not shown). However, sTNFR:Fc treatment
of RAW264.7 macrophages at concentrations above 1 μg/ml resulted
in suppression of TNF secretion and in a significant induction of
IFN-γ and IL-10 elaboration, with no changes in MCP-1, IL-6, and
IL-12p70 expression (Figure 6), paralleling the in vivo changes observed
after sTNFR:Fc treatment. These results suggested that sTNFR:Fc ef-
fects on pulmonary macrophages may mediate its immunomodulatory
effects during urethane-induced lung oncogenesis and may contribute
to the tumor-protective impact of TNF blockade.
Discussion
In the present work, we set out to investigate the impact of TNF bio-
activity neutralization on urethane-induced lung oncogenesis in mice.
Base on previous reports of tumor-protective effects of genetic TNF
deficiency in this model, of pulmonary TNF expression after urethane
exposure of mice, and of TNF and TNFR expression in lung cancer,
we hypothesized that TNF signals promote the formation and progres-
sion of lung tumors in response to the prototype carcinogen urethane.
To test this, we used different pharmacologic dosing protocols of a
clinically available TNF inhibitor, designed to target distinct stages
of urethane-induced respiratory carcinogenesis. We found that this
strategy was effective in halting pulmonary oncogenesis across its whole
timeline spectrum, ranging from tumor initiation of the naive respira-
tory epithelium to progression of already established neoplastic lesions.
Moreover, the effects of TNF blockade were associated with decreased
lung tumor cellular proliferation, impaired tumor-associated angio-
genesis, and modulation of tumor-accompanying inflammation. Some
of our in vivo observations regarding regulation of inflammatory sig-
nals after urethane were further recapitulated in mouse macrophages
in culture, suggesting that alveolar macrophages may be involved in
the favorable effects of TNF neutralization.
This report complements and corroborates previous work that showed
that Tnf gene-deficient mice are protected from urethane-induced lung
tumorigenesis [16]. Moreover, our results show that the protumorigenic
functions of TNF signaling during chemical-induced lung carcinogenesis
can be therapeutically targeted to yield clinically relevant beneficial ef-
fects. In our hands, the latter were not confined to prevention of forma-
tion of de novo neoplastic lesions, as evidenced by the reduction in tumor
multiplicity in our initiation trial, but also included regression of already
present preneoplastic and neoplastic lesions, as indicated by the reduc-
tions in tumor size and in the relative abundance of more progressed
adenoma lesions in mice from our regression trial. Importantly, TNF
neutralization could be safely applied during the whole timeline of
urethane-induced respiratory oncogenesis without apparent toxicities,
yielding favorable effects on both new neoplastic lesion formation and
progression of preexisting tumors in the lungs.
Figure 4. Effects of TNF signaling blockade on air space inflammatory parameters in the tumor-bearing lungs of urethane-treated mice.
Balb/c mice were treated as outlined under Figure 1A. (A) Bronchoalveolar lavage (BAL) absolute cell numbers. MΦ indicates macro-
phages; PMN, neutrophil polymorphonuclear leukocytes; LΦ, lymphocytes. (B) BAL levels of TNF, IFN-γ, and IL-10. Dots indicate raw
data points; lines, mean; bars, SEM; P, overall probability. *P < .05, **P < .01, and ***P < .001 compared with control.
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Inflammation, initially thought to exert antitumorigenic functions
of immune surveillance and immune rejection, was, in recent years,
found to accompany solid tumors starting from their development
up to advanced metastatic progression stages [26]. Moreover, the in-
flammatory response to tumor development is not a mere bystander
but seems to promote tumor formation, growth, and metastasis
through blunting and co-option of, and escape from, host antitumor
immunity [27]. Inflammation is so important in cancer biology that
it was recently incorporated into the updated hallmarks of cancer as
a conditional hallmark [25]. Our results are directly relevant with
the concept of tumor-promoting inflammation. First, by targeting
TNF, a cardinal proinflammatory mediator, we obtained marked
suppression of chemical-induced lung tumorigenesis. Second, our
interventions did not only result in cell-autonomous effects on tumor
cells (reduced growth rate) but also seemed to globally impact the
host milieu of lung tumor development, significantly modulating the
inflammatory response to the chemical carcinogen urethane and im-
pairing the formation of new blood vessels. In particular, sTNFR:Fc-
mediated TNF neutralization augmented the local release of IFN-γ
and IL-10 in the airway lumen, mediators of proven antitumorigenic
functions [23,24]. Third, we provide some evidence suggesting that
the effects of our interventions may not be limited to respiratory epi-
thelium and tumor cells but may extend to inflammatory cells within
the tumor microenvironment. In this regard, the changes in the inflam-
matory response observed in the air spaces of mice after sTNFR:Fc
treatment were closely recapitulated by sTNFR:Fc treatment of macro-
phages in vitro.
TNF is currently considered to be a major promoter of cancer pro-
gression [10]. Although earlier experiments pointed toward beneficial
antitumor effects of the cytokine [9], it was later shown that physiologi-
cally irrelevant high doses were required for induction of tumor necrosis
[28]. Instead, physiological low levels of TNF, such as produced by
both tumor and host stromal cells (e.g., tumor-infiltrating macro-
phages), were found to promote tumor growth and metastasis in
several sites [11–13,29,30]. Current evidence indicates that the tumor-
promoting actions of TNF are directed toward both cancer cells and
the host microenvironment in which the tumors grow. For example,
TNF activates NF-κB in tumor cells, thereby promoting cell growth,
preventing apoptosis, and inducing immortalization [11,13,31]. In
addition, TNF impacts the host milieu by inducing angiogenesis and
vascular hyperpermeability and by altering the phenotype of tumor-
infiltrating macrophages and other immune cells [13,32,33]. As opposed
to established cancer progression, far less is known on the effects of
TNF on early stages of tumor development, that is, carcinogenesis
[16,34]. Moreover, only few attempts at biologic TNF blockade in
mouse models of carcinogenesis have been made [35]. We show that
sTNFR:Fc treatment is effective against urethane-induced carcino-
genesis, even when given during the earliest stages of respiratory epithelial
tumor initiation. In combination with the existing literature, our re-
sults lend hope that TNF blockade may constitute in the future a viable
strategy for tumor prevention and therapy.
A main obstacle in applying anti-TNF therapies to tumor thera-
peutics or even chemoprevention design is the cytokine’s name: TNF
blockade may enhance carcinogenesis instead of curing it. In face of
current evidence, these fears seem unsubstantiated. TNF antagonists
Figure 6. Effects of sTNFR:Fc treatment on mouse macrophages in vitro. RAW264.7 mouse macrophages were cultured with varying con-
centrations of sTNFR:Fc. After 24 hours, supernatants were collected for cytokine determinations by cytometric bead array, and cells were
lysed for protein assay. The experiment was done thrice (n = 3). TNF indicates tumor necrosis factor; IL, interleukin; IFN, interferon. Dots
indicate mean; bars, SEM. ***P < .001 compared with no treatment (0 μg/ml sTNFR:Fc).
Figure 5. Effects of sTNFR:Fc on urethane-induced subacute lung
inflammation. Balb/c mice were treated as outlined under Figure 1B.
(A) Bronchoalveolar lavage (BAL) absolute cell numbers. MΦ indi-
cates macrophages; PMN, neutrophil polymorphonuclear leuko-
cytes; LΦ, lymphocytes. (B) BAL levels of TNF, IFN-γ, and IL-10. Dots
indicate raw data points; lines, mean; bars, SEM; P, overall probabil-
ity. *P< .05, **P< .01, and ***P< .001 compared with control.
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have been used for prolonged periods in patients with autoimmune
joint disorders. The only adverse events observed were restricted to
infectious disease reactivation or skewed autoimmunity, and no in-
creased risk of epithelial malignancies was recorded [36–38]. In addi-
tion to being safe, TNF blockade seems to exert promising effects, by
inducing disease stability in a significant subset of patients, or by even
ameliorating the adverse effects of chemotherapy [19,39–42]. While
the acquisition of a better understanding of the impact of TNF in
human cancer and its relative importance in early versus late cancers is
ongoing, our results add to the existing literature regarding the potential
benefits of TNF neutralization during early stages of carcinogenesis.
In the lungs, chronic inflammatory diseases, such as COPD, are
most likely causally related with lung cancer development [6]. Patients
with COPD run a three to five times greater risk of being diagnosed
with lung cancer independent from smoking intensity and dura-
tion [43]. In fact, although only 20% of smokers develop COPD,
more than half of lung cancers coincide in patients with COPD [44].
Vice versa, more than 50% of patients with lung cancer are also diag-
nosed with COPD at the time of tumor diagnosis [45]. Recently,
common paths to both COPD and lung cancer have been unveiled,
including respiratory epithelial NF-κB activation [6,15,46]. TNF, a
marked transcriptional target of NF-κB, is expressed in both COPD
and lung cancer and is a lucrative candidate culprit for the inflammatory
lung carcinogenesis observed in smokers and patients with COPD
[14,47]. Although TNF antagonists have failed to inhibit the chronic
inflammation behind COPD and to yield a clinically relevant benefit,
they might be effective as chemopreventive agents in these patients [48].
In this regard, inhaled corticosteroids, the prototype respiratory anti-
inflammatory drugs, have failed to halt COPD [49], but evidence
suggests they might be useful for chemoprevention against lung can-
cer [50]. More importantly, the results from our tumor progression
trial suggest that TNF antagonism may hold promise in secondary
chemoprevention, that is, in patients with resected lung cancer that
run increased risk for the development of a second primary tumor.
In conclusion, we showed that a clinically safe and available TNF
antagonist is effective in limiting chemical respiratory carcinogenesis
induced by urethane in mice. Collectively, our results and previous
work that used genetic TNF targeting suggest that TNF may present
an important target for lung cancer chemoprevention in the future.
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